Home Newsfeeds Barclays Upgrades Helmerich & Payne to Overweight

Barclays Upgrades Helmerich & Payne to Overweight

Barclays analyst David Anderson upgrades Helmerich & Payne (NYSE:HP) from Equal-Weight to Overweight.

byBenzinga Newsdesk

July 14, 2022

1 minute read

Barclays analyst David Anderson upgrades Helmerich & Payne (NYSE:HP) from Equal-Weight to Overweight.

News
Tech

A New Tech Could Fix The Two Major Issues With OLED Screens Of Smartphones And TVs

By Rounak Jain

December 26, 9:07 AM

A new technology called PHOLED is on the horizon, promising to fix problems associated with OLED displays.

OLED

Datasea Q2 EPS $(0.05) Up From $(0.07) YoY, Sales $425.71K Down From $8.98M YoY

By Happy Mohamed

February 13, 5:34 PM

Datasea (NASDAQ:DTSS) reported quarterly losses of $(0.05) per share. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported $425.71 thousand in sales this

DTSS

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

May 30, 1:27 PM

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.

AAIC

First Patient Dosed In Trial Evaluating Efti And The Anti-PD-L1 Therapy BAVENCIO In Metastatic Urothelial Cancer

By Benzinga Newsdesk

January 4, 9:17 AM

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first

IMMP

Barclays Upgrades Helmerich & Payne to Overweight

Related Posts

A New Tech Could Fix The Two Major Issues With OLED Screens Of Smartphones And TVs

Datasea Q2 EPS $(0.05) Up From $(0.07) YoY, Sales $425.71K Down From $8.98M YoY

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

First Patient Dosed In Trial Evaluating Efti And The Anti-PD-L1 Therapy BAVENCIO In Metastatic Urothelial Cancer